• Explore /
  • Poster
  • / Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.

Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.

Abstract Poster

Authors

null

Alberto Bessudo

Pacific Oncology Hematology Associates Inc., Encinitas, CA

Alberto Bessudo , Ezra E.W. Cohen , Rodolfo Gutierrez , Daniel H. Johnson , Ari Rosenberg , Benjamin Adam Weinberg , Susanna Varkey Ulahannan , Hadas Reuveni , Michael Schickler , Bertrand C. Liang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT04474470

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3096)

DOI

10.1200/JCO.2022.40.16_suppl.3096

Abstract #

3096

Poster Bd #

88

Abstract Disclosures

Similar Posters

First Author: Susanna Varkey Ulahannan

First Author: Erin Marie Bertino

First Author: Antoine Hollebecque

First Author: Jermaine Coward